Talk Title: Omics Convergence in Cancer Research: Advances in Precision Medicine
Dr. Rodriguez is Director of the Office of Cancer Clinical Proteomics Research at the National Cancer Institute (NCI), National Institutes of Health (NIH). Dr. Rodriguez has played a key role in NCI’s clinical proteomics research programs, which today includes the world’s largest public repository of proteogenomic sequence data and targeted proteomic assays. Dr. Rodriguez co-lead the development of the Applied Proteogenomics OrganizationaL Learning and Outcomes network (APOLLO) and International Cancer Proteogenome Consortium (ICPC) for the Beau Biden Cancer Moonshot effort. Dr. Rodriguez has numerous honors and awards, and has authored more than 121 peer-reviewed original research papers, including co-editing a best-selling book on oxidative stress. Dr. Rodriguez received his B.S. in biology/chemistry and M.S. in biology/toxicology from Florida International University, Ph.D. in cell and molecular biology from Boston University, and M.B.A. in finance and management from Johns Hopkins University Carey Business School. Research fellowships were conducted at The Scripps Research Institute and at City of Hope National Medical Cancer Center.
Despite significant progress in understanding cancer through massively parallel sequencing genome programs, the complexity that comprises its diseases remains a daunting barrier. Today we know that molecular drivers of cancer are derived not just from DNA alterations alone, but from protein expression and activity at the cellular pathway level – proteomics. To predict the downstream effects of gene alterations, orthogonal technologies such as next-generation proteomics are needed. This proteogenomics approach (interplay between proteome and genome) is anticipated to transform oncology care from one that relies mainly on trial-and-error treatment strategies based on the anatomy of the tumor, to one that is more precisely based on the tumor’s molecular profile. This seminar will discuss how genomics, transcriptomics, and proteomics must all be brought together in the quest to understand the etiology of cancer, in addition to highlighting efforts by the U.S. National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) program in this area of biomedical research. CPTAC’s proteogenomics approach was recently successful in demonstrating the scientific benefits of integrating proteomics with genomics to produce a more unified understanding of cancer biology and possibly therapeutic interventions for patients, while creating open community resources that are widely used by the global cancer community. This seminar will also highlight the recently announced APOLLO (Applied Proteogenomics OrganizationaL Learning and Outcomes) program and the efforts of the International Proteogenomic Consortium. APOLLO brings together the U.S. National Cancer Institute, U.S. Department of Defense, and the U.S. Department of Veterans Affairs to create the nation’s first healthcare system in which cancer patients will be routinely screened for genomic abnormalities and proteomic information with the goal of matching their tumor type to a specific targeted therapy.